Literature DB >> 21281226

De novo acute myeloid leukemia with Philadelphia chromosome (BCR-ABL) and inversion 16 (CBFB-MYH11): report of two cases and review of the literature.

Christine G Roth, Lydia Contis, Saurabh Gupta, Mounzer Agha, Eric Safyan.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21281226     DOI: 10.3109/10428194.2010.538941

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


× No keyword cloud information.
  5 in total

1.  p210 BCR/ABL1 as a secondary change in a patient with acute myelomonocytic leukemia (M4Eo) with inv(16).

Authors:  Hai-ping Dai; Yong-quan Xue; Li-li Wu; Jin-lan Pan; Yan-lei Gong; Ya-fang Wu; Jun Zhang; De-pei Wu; Su-ning Chen
Journal:  Int J Hematol       Date:  2012-10-11       Impact factor: 2.490

Review 2.  Coexistence of inversion 16 and the Philadelphia chromosome comprising P190 BCR/ABL in chronic myeloid leukemia blast crisis.

Authors:  Soranobu Ninomiya; Nobuhiro Kanemura; Hisashi Tsurumi; Senji Kasahara; Takeshi Hara; Toshiki Yamada; Hisataka Moriwaki
Journal:  Int J Hematol       Date:  2011-04-27       Impact factor: 2.490

3.  t(9;22) as secondary alteration in core-binding factor de novo acute myeloid leukemia.

Authors:  Candida Vitale; Xinyan Lu; Balkees Abderrahman; Koichi Takahashi; Farhad Ravandi; Elias Jabbour
Journal:  Am J Hematol       Date:  2015-10-12       Impact factor: 10.047

4.  Characteristics of hematologic malignancies with coexisting t(9;22) and inv(16) chromosomal abnormalities.

Authors:  Eunhee Han; Hyeyoung Lee; Myungshin Kim; Yonggoo Kim; Kyungja Han; Sung-Eun Lee; Hee-Je Kim; Dong-Wook Kim
Journal:  Blood Res       Date:  2014-03-24

5.  Coexistence of p210BCR-ABL and CBFβ-MYH11 fusion genes in myeloid leukemia: A report of 4 cases.

Authors:  Yuan-Yuan Wang; Wen-Jing Ding; Feng Jiang; Zi-Xing Chen; Jian-Nong Cen; Xiao-Fei Qi; Jian-Ying Liang; Dan-Dan Liu; Jin-Lan Pan; Su-Ning Chen
Journal:  Oncol Lett       Date:  2017-08-24       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.